Growth hormone treatment improves body composition in adults with Prader-Willi syndrome
Summary objective Low growth hormone (GH) secretion and hypogonadism are common in patients with Prader–Willi syndrome (PWS). In this study we present the effects of GH treatment on body composition and metabolism in adults with PWS. patients and measurements Nineteen patients with clinical PWS were...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2003-05, Vol.58 (5), p.653-661 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 661 |
|---|---|
| container_issue | 5 |
| container_start_page | 653 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 58 |
| creator | Höybye, Charlotte Hilding, Agneta Jacobsson, Hans Thorén, Marja |
| description | Summary
objective Low growth hormone (GH) secretion and hypogonadism are common in patients with Prader–Willi syndrome (PWS). In this study we present the effects of GH treatment on body composition and metabolism in adults with PWS.
patients and measurements Nineteen patients with clinical PWS were recruited, 13 had PWS genotype. They were randomised to treatment with placebo or GH (Genotropin®, Pharmacia Corporation, Sweden) 0·8 IU (0·2 mg) daily for 1 month and then 1·6 IU (0·5 mg) daily for 5 months. Thereafter patients recieved open label treatment so that all had 12 months of active GH treatment. Doses were individually titrated to keep serum IGF‐I within the normal range for age. Body composition using dual energy X‐ray absorptiometry (DXA), metabolic and endocrinological parameters, including oral glucose tolerance test (OGTT), were studied every 6 months. Seventeen patients, nine men and eight women, 17–32 years of age, with a mean body mass index (BMI) of 35 ± 3·2 kg/m2 completed the study.
results Compared to placebo, GH treatment increased IGF‐I (P |
| doi_str_mv | 10.1046/j.1365-2265.2003.01769.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_590169</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>340614181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4989-ab072ccd5f5358d3097db9daa10c54cb3b90974b747e530a50b61e841aefb4183</originalsourceid><addsrcrecordid>eNqNkc2O0zAURi0EYsrAK6AICXYJ1_FfvGCBqqEgjQaoQJXYWE7iaNxJ4mIntH17nGnUSqxY-co-37WvD0IJhgwD5e-3GSacpXnOWZYDkAyw4DI7PEGL88FTtAACkALn9Aq9CGELAKwA8Rxd4ZxLSRks0Gbl3X64T-6d71xvksEbPXSmHxLb7bz7Y0JSuvqYVK7buWAH6_rE9omux3YIyd7G6Deva-PTjW1bm4RjX3vXmZfoWaPbYF7N6zX6-enmx_Jzevt19WX58TatqCxkqksQeVXVrGGEFTUBKepS1lpjqBitSlLKuEVLQYVhBDSDkmNTUKxNU1JckGuUnvqGvdmNpdp522l_VE5bNW89xMooJgFzGfl3Jz4O93s0YVCdDZVpW90bNwYlCJYFKVgE3_wDbt3o-ziLigSXuXiEihNUeReCN835fgxqMqW2ahKiJiFqMqUeTalDjL6e-49lZ-pLcFYTgbczoEOl28brvrLhwlFB8yKnkftw4va2Ncf_foBa3txN1eUHbRjM4ZzX_kFxQQRTm7uVWhWb77_W67Vi5C9wOL8j</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198692785</pqid></control><display><type>article</type><title>Growth hormone treatment improves body composition in adults with Prader-Willi syndrome</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Höybye, Charlotte ; Hilding, Agneta ; Jacobsson, Hans ; Thorén, Marja</creator><creatorcontrib>Höybye, Charlotte ; Hilding, Agneta ; Jacobsson, Hans ; Thorén, Marja</creatorcontrib><description>Summary
objective Low growth hormone (GH) secretion and hypogonadism are common in patients with Prader–Willi syndrome (PWS). In this study we present the effects of GH treatment on body composition and metabolism in adults with PWS.
patients and measurements Nineteen patients with clinical PWS were recruited, 13 had PWS genotype. They were randomised to treatment with placebo or GH (Genotropin®, Pharmacia Corporation, Sweden) 0·8 IU (0·2 mg) daily for 1 month and then 1·6 IU (0·5 mg) daily for 5 months. Thereafter patients recieved open label treatment so that all had 12 months of active GH treatment. Doses were individually titrated to keep serum IGF‐I within the normal range for age. Body composition using dual energy X‐ray absorptiometry (DXA), metabolic and endocrinological parameters, including oral glucose tolerance test (OGTT), were studied every 6 months. Seventeen patients, nine men and eight women, 17–32 years of age, with a mean body mass index (BMI) of 35 ± 3·2 kg/m2 completed the study.
results Compared to placebo, GH treatment increased IGF‐I (P < 0·01) levels and decreased body fat (P = 0·04). When all patients recieved GH treatment a mean reduction in body fat of 2·5% (P < 0·01) concomitant with a mean increase in lean body mass of 2·2 kg (P < 0·05) was seen. Significant changes in body composition were only seen in the patients with the PWS genotype. Lipid profiles were normal in most patients before treatment and did not change. OGTT was impaired in five patients at 12 months, but two of these patients increased in fat mass. Insulin levels were unchanged. According to homeostasis model assessment (HOMA), insulin resistance did not change. Side‐effects attributed to water retention occurred in three patients, one of whom had to be given increased diuretic therapy.
conclusion This study shows beneficial effects of GH treatment on body composition in adult PWS patients without significant side‐effects. Consequently, further studies are encouraged.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1046/j.1365-2265.2003.01769.x</identifier><identifier>PMID: 12699450</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adipose Tissue - drug effects ; Adolescent ; Adult ; Biological and medical sciences ; Body Composition - drug effects ; Body Mass Index ; Complex syndromes ; Drug Administration Schedule ; Female ; Genotype ; Glucose Tolerance Test ; Homeostasis - physiology ; Hormones. Endocrine system ; Human Growth Hormone - adverse effects ; Human Growth Hormone - therapeutic use ; Humans ; Insulin Resistance - physiology ; Insulin-Like Growth Factor I - analysis ; Lipids - analysis ; Male ; Medical genetics ; Medical sciences ; Methylation ; Pharmacology. Drug treatments ; Prader-Willi Syndrome - drug therapy ; Prader-Willi Syndrome - physiopathology ; Weight Gain - drug effects</subject><ispartof>Clinical endocrinology (Oxford), 2003-05, Vol.58 (5), p.653-661</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. May 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4989-ab072ccd5f5358d3097db9daa10c54cb3b90974b747e530a50b61e841aefb4183</citedby><cites>FETCH-LOGICAL-c4989-ab072ccd5f5358d3097db9daa10c54cb3b90974b747e530a50b61e841aefb4183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2265.2003.01769.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2265.2003.01769.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,778,782,883,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14742824$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12699450$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1940864$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Höybye, Charlotte</creatorcontrib><creatorcontrib>Hilding, Agneta</creatorcontrib><creatorcontrib>Jacobsson, Hans</creatorcontrib><creatorcontrib>Thorén, Marja</creatorcontrib><title>Growth hormone treatment improves body composition in adults with Prader-Willi syndrome</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Summary
objective Low growth hormone (GH) secretion and hypogonadism are common in patients with Prader–Willi syndrome (PWS). In this study we present the effects of GH treatment on body composition and metabolism in adults with PWS.
patients and measurements Nineteen patients with clinical PWS were recruited, 13 had PWS genotype. They were randomised to treatment with placebo or GH (Genotropin®, Pharmacia Corporation, Sweden) 0·8 IU (0·2 mg) daily for 1 month and then 1·6 IU (0·5 mg) daily for 5 months. Thereafter patients recieved open label treatment so that all had 12 months of active GH treatment. Doses were individually titrated to keep serum IGF‐I within the normal range for age. Body composition using dual energy X‐ray absorptiometry (DXA), metabolic and endocrinological parameters, including oral glucose tolerance test (OGTT), were studied every 6 months. Seventeen patients, nine men and eight women, 17–32 years of age, with a mean body mass index (BMI) of 35 ± 3·2 kg/m2 completed the study.
results Compared to placebo, GH treatment increased IGF‐I (P < 0·01) levels and decreased body fat (P = 0·04). When all patients recieved GH treatment a mean reduction in body fat of 2·5% (P < 0·01) concomitant with a mean increase in lean body mass of 2·2 kg (P < 0·05) was seen. Significant changes in body composition were only seen in the patients with the PWS genotype. Lipid profiles were normal in most patients before treatment and did not change. OGTT was impaired in five patients at 12 months, but two of these patients increased in fat mass. Insulin levels were unchanged. According to homeostasis model assessment (HOMA), insulin resistance did not change. Side‐effects attributed to water retention occurred in three patients, one of whom had to be given increased diuretic therapy.
conclusion This study shows beneficial effects of GH treatment on body composition in adult PWS patients without significant side‐effects. Consequently, further studies are encouraged.</description><subject>Adipose Tissue - drug effects</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Body Composition - drug effects</subject><subject>Body Mass Index</subject><subject>Complex syndromes</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Genotype</subject><subject>Glucose Tolerance Test</subject><subject>Homeostasis - physiology</subject><subject>Hormones. Endocrine system</subject><subject>Human Growth Hormone - adverse effects</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Insulin Resistance - physiology</subject><subject>Insulin-Like Growth Factor I - analysis</subject><subject>Lipids - analysis</subject><subject>Male</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Methylation</subject><subject>Pharmacology. Drug treatments</subject><subject>Prader-Willi Syndrome - drug therapy</subject><subject>Prader-Willi Syndrome - physiopathology</subject><subject>Weight Gain - drug effects</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc2O0zAURi0EYsrAK6AICXYJ1_FfvGCBqqEgjQaoQJXYWE7iaNxJ4mIntH17nGnUSqxY-co-37WvD0IJhgwD5e-3GSacpXnOWZYDkAyw4DI7PEGL88FTtAACkALn9Aq9CGELAKwA8Rxd4ZxLSRks0Gbl3X64T-6d71xvksEbPXSmHxLb7bz7Y0JSuvqYVK7buWAH6_rE9omux3YIyd7G6Deva-PTjW1bm4RjX3vXmZfoWaPbYF7N6zX6-enmx_Jzevt19WX58TatqCxkqksQeVXVrGGEFTUBKepS1lpjqBitSlLKuEVLQYVhBDSDkmNTUKxNU1JckGuUnvqGvdmNpdp522l_VE5bNW89xMooJgFzGfl3Jz4O93s0YVCdDZVpW90bNwYlCJYFKVgE3_wDbt3o-ziLigSXuXiEihNUeReCN835fgxqMqW2ahKiJiFqMqUeTalDjL6e-49lZ-pLcFYTgbczoEOl28brvrLhwlFB8yKnkftw4va2Ncf_foBa3txN1eUHbRjM4ZzX_kFxQQRTm7uVWhWb77_W67Vi5C9wOL8j</recordid><startdate>200305</startdate><enddate>200305</enddate><creator>Höybye, Charlotte</creator><creator>Hilding, Agneta</creator><creator>Jacobsson, Hans</creator><creator>Thorén, Marja</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>200305</creationdate><title>Growth hormone treatment improves body composition in adults with Prader-Willi syndrome</title><author>Höybye, Charlotte ; Hilding, Agneta ; Jacobsson, Hans ; Thorén, Marja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4989-ab072ccd5f5358d3097db9daa10c54cb3b90974b747e530a50b61e841aefb4183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adipose Tissue - drug effects</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Body Composition - drug effects</topic><topic>Body Mass Index</topic><topic>Complex syndromes</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Genotype</topic><topic>Glucose Tolerance Test</topic><topic>Homeostasis - physiology</topic><topic>Hormones. Endocrine system</topic><topic>Human Growth Hormone - adverse effects</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Insulin Resistance - physiology</topic><topic>Insulin-Like Growth Factor I - analysis</topic><topic>Lipids - analysis</topic><topic>Male</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Methylation</topic><topic>Pharmacology. Drug treatments</topic><topic>Prader-Willi Syndrome - drug therapy</topic><topic>Prader-Willi Syndrome - physiopathology</topic><topic>Weight Gain - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Höybye, Charlotte</creatorcontrib><creatorcontrib>Hilding, Agneta</creatorcontrib><creatorcontrib>Jacobsson, Hans</creatorcontrib><creatorcontrib>Thorén, Marja</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Höybye, Charlotte</au><au>Hilding, Agneta</au><au>Jacobsson, Hans</au><au>Thorén, Marja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth hormone treatment improves body composition in adults with Prader-Willi syndrome</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2003-05</date><risdate>2003</risdate><volume>58</volume><issue>5</issue><spage>653</spage><epage>661</epage><pages>653-661</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>Summary
objective Low growth hormone (GH) secretion and hypogonadism are common in patients with Prader–Willi syndrome (PWS). In this study we present the effects of GH treatment on body composition and metabolism in adults with PWS.
patients and measurements Nineteen patients with clinical PWS were recruited, 13 had PWS genotype. They were randomised to treatment with placebo or GH (Genotropin®, Pharmacia Corporation, Sweden) 0·8 IU (0·2 mg) daily for 1 month and then 1·6 IU (0·5 mg) daily for 5 months. Thereafter patients recieved open label treatment so that all had 12 months of active GH treatment. Doses were individually titrated to keep serum IGF‐I within the normal range for age. Body composition using dual energy X‐ray absorptiometry (DXA), metabolic and endocrinological parameters, including oral glucose tolerance test (OGTT), were studied every 6 months. Seventeen patients, nine men and eight women, 17–32 years of age, with a mean body mass index (BMI) of 35 ± 3·2 kg/m2 completed the study.
results Compared to placebo, GH treatment increased IGF‐I (P < 0·01) levels and decreased body fat (P = 0·04). When all patients recieved GH treatment a mean reduction in body fat of 2·5% (P < 0·01) concomitant with a mean increase in lean body mass of 2·2 kg (P < 0·05) was seen. Significant changes in body composition were only seen in the patients with the PWS genotype. Lipid profiles were normal in most patients before treatment and did not change. OGTT was impaired in five patients at 12 months, but two of these patients increased in fat mass. Insulin levels were unchanged. According to homeostasis model assessment (HOMA), insulin resistance did not change. Side‐effects attributed to water retention occurred in three patients, one of whom had to be given increased diuretic therapy.
conclusion This study shows beneficial effects of GH treatment on body composition in adult PWS patients without significant side‐effects. Consequently, further studies are encouraged.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>12699450</pmid><doi>10.1046/j.1365-2265.2003.01769.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2003-05, Vol.58 (5), p.653-661 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_590169 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adipose Tissue - drug effects Adolescent Adult Biological and medical sciences Body Composition - drug effects Body Mass Index Complex syndromes Drug Administration Schedule Female Genotype Glucose Tolerance Test Homeostasis - physiology Hormones. Endocrine system Human Growth Hormone - adverse effects Human Growth Hormone - therapeutic use Humans Insulin Resistance - physiology Insulin-Like Growth Factor I - analysis Lipids - analysis Male Medical genetics Medical sciences Methylation Pharmacology. Drug treatments Prader-Willi Syndrome - drug therapy Prader-Willi Syndrome - physiopathology Weight Gain - drug effects |
| title | Growth hormone treatment improves body composition in adults with Prader-Willi syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A07%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20hormone%20treatment%20improves%20body%20composition%20in%20adults%20with%20Prader-Willi%20syndrome&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=H%C3%B6ybye,%20Charlotte&rft.date=2003-05&rft.volume=58&rft.issue=5&rft.spage=653&rft.epage=661&rft.pages=653-661&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1046/j.1365-2265.2003.01769.x&rft_dat=%3Cproquest_swepu%3E340614181%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198692785&rft_id=info:pmid/12699450&rfr_iscdi=true |